Analysis of the standard dosage and medication regimen of Ixazomib (Enleri)

Ixazomib (Ixazomib) is an oral reversible proteasome inhibitor mainly used for the treatment of multiple myeloma. It is usually used in combination with lenalidomide (Lenalidomide) and dexamethasone (Dexamethasone). Its unique oral administration method is more convenient than traditional intravenous proteasome inhibitors, is suitable for long-term maintenance treatment, and can also improve patients' quality of life.

In the standard treatment regimen, the recommended dose of ixazomib is 4 mg orally once weekly (usually on days 1, 8, 15). The drug should be taken on an empty stomach or with food, but the tablet must be swallowed whole and not chewed or crushed. Usually a treatment cycle lasts for 28 days and is used in combination with lenalidomide and dexamethasone to exert a synergistic anti-tumor effect and reduce the risk of recurrence.

In patients with impaired renal function, the ixazomib dose may need to be adjusted. Mild to moderate renal insufficiency (creatinine clearance 30–59 mL/min) generally does not require dose adjustment; patients with severe renal insufficiency (creatinine clearance <30 mL/min) or patients receiving dialysis should use it with caution and consider dose reduction under the guidance of a physician. In addition, if serious hematological or non-hematological adverse reactions occur, the dose must be suspended or adjusted to ensure patient safety.

During use, patients should regularly monitor blood routine, liver and kidney function, and neurological symptoms, paying special attention to the risk of peripheral neuropathy and thrombocytopenia. Once obvious side effects occur, you should promptly communicate with your doctor to adjust the plan. By standardizing dose and cycle management, ixazomib can achieve better efficacy while taking into account safety, providing an effective long-term maintenance treatment plan for patients with multiple myeloma.

Reference materials:https://www.drugs.com/